{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:02Z","timestamp":1786982762375,"version":"build-2736575974"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40263-025-01214-3","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T13:11:34Z","timestamp":1757855494000},"page":"1061-1070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Methamphetamine Pharmacotherapy: A Need to Re-focus on the Complex Neurobiological Changes that Occur Both During and After Methamphetamine Use Disorder"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2833-4830","authenticated-orcid":false,"given":"Rebecca","family":"McKetin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyna","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,14]]},"reference":[{"key":"1214_CR1","doi-asserted-by":"publisher","DOI":"10.18356\/9789211065602","volume-title":"World drug report 2024","author":"United Nations Office on Drugs and Crime","year":"2024","unstructured":"United Nations Office on Drugs and Crime. World drug report 2024. Vienna: United Nations; 2024."},{"key":"1214_CR2","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/S0140-6736(19)32230-5","volume":"394","author":"M Farrell","year":"2019","unstructured":"Farrell M, Martin NK, Stockings E, Borquez A, Cepeda JA, Degenhardt L, et al. Responding to global stimulant use: challenges and opportunities. Lancet. 2019;394:1652\u201367.","journal-title":"Lancet"},{"key":"1214_CR3","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edn. Arlington, VA: American Psychiatric Association; 2013. dsm.psychiatryonline.org. Accessed 1 June 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1214_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.addbeh.2018.01.021","volume":"80","author":"S Potvin","year":"2018","unstructured":"Potvin S, Pelletier J, Grot S, H\u00e9bert C, Barr AM, Lecomte T. Cognitive deficits in individuals with methamphetamine use disorder: a meta-analysis. Addict Behav. 2018;80:154\u201360.","journal-title":"Addict Behav"},{"key":"1214_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.drugalcdep.2018.08.041","volume":"194","author":"S Sabrini","year":"2019","unstructured":"Sabrini S, Wang GY, Lin JC, Ian JK, Curley LE. Methamphetamine use and cognitive function: a systematic review of neuroimaging research. Drug Alcohol Depend. 2019;194:75\u201387.","journal-title":"Drug Alcohol Depend"},{"key":"1214_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/wps.20457","volume":"16","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Glantz M, Evans-Lacko S, Sadikova E, Sampson N, Thornicroft G, et al. Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. World Psychiatry. 2017;16:299\u2013307.","journal-title":"World Psychiatry"},{"key":"1214_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.drugalcdep.2016.10.001","volume":"168","author":"C Cumming","year":"2016","unstructured":"Cumming C, Troeung L, Young JT, Kelty E, Preen DB. Barriers to accessing methamphetamine treatment: a systematic review and meta-analysis. Drug Alcohol Depend. 2016;168:263\u201373.","journal-title":"Drug Alcohol Depend"},{"key":"1214_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.addicn.2023.100064","volume":"5","author":"MM St. Peters","year":"2023","unstructured":"St. Peters MM, Park CHJ, Turner A, Guerin AA, Kim JH. Past and current drug repurposing clinical trials to treat cognition in methamphetamine use: a scoping review of pharmacotherapy candidates. Addict Neurosci. 2023;5: 100064.","journal-title":"Addict Neurosci"},{"key":"1214_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","volume":"34","author":"KJ Siefried","year":"2020","unstructured":"Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review. CNS Drugs. 2020;34:337\u201365.","journal-title":"CNS Drugs"},{"key":"1214_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.pneurobio.2005.04.003","volume":"75","author":"D Sulzer","year":"2005","unstructured":"Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75:406\u201333.","journal-title":"Prog Neurobiol"},{"key":"1214_CR11","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394:1560\u201379.","journal-title":"Lancet"},{"key":"1214_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bcp.12051","volume":"77","author":"J Bell","year":"2014","unstructured":"Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol. 2014;77:253\u201363.","journal-title":"Br J Clin Pharmacol"},{"key":"1214_CR13","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014:Cd002207.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"1214_CR14","unstructured":"Unodc NDF. #ScaleUp\u2014UNODC initiative on promoting scalable and effective interventions for the treatment of stimulants use disorders: United Nations; 2024."},{"key":"1214_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/add.13158","volume":"111","author":"S Darke","year":"2016","unstructured":"Darke S, Farrell M. Which medications are suitable for agonist drug maintenance? Addiction. 2016;111:767\u201374.","journal-title":"Addiction"},{"key":"1214_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/add.16416","volume":"119","author":"W Hall","year":"2024","unstructured":"Hall W, Darke S, Farrell M. Do we need clinical trials of high dose stimulant agonist treatment for stimulant use disorders? Addiction. 2024;119:786\u20137.","journal-title":"Addiction"},{"key":"1214_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/09595239500185531","volume":"14","author":"RP Mattick","year":"1995","unstructured":"Mattick RP, Darke S. Drug replacement treatments: is amphetamine substitution a horse of a different colour? Drug Alcohol Rev. 1995;14:389\u201394.","journal-title":"Drug Alcohol Rev"},{"key":"1214_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/add.16347","volume":"119","author":"H Sharafi","year":"2024","unstructured":"Sharafi H, Bakouni H, Mcanulty C, Drouin S, Coronado-Montoya S, Bahremand A, et al. Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: a systematic review and meta-analysis of randomized placebo-controlled trials. Addiction. 2024;119:211\u201324.","journal-title":"Addiction"},{"key":"1214_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/add.16730","author":"N Ezard","year":"2025","unstructured":"Ezard N, Clifford B, Siefried K, Ali R, Dunlop A, Mcketin R, et al. Lisdexamfetamine in the treatment of methamphetamine dependence: a randomised, placebo-controlled trial. Addiction. 2025. https:\/\/doi.org\/10.1111\/add.16730.","journal-title":"Addiction"},{"key":"1214_CR20","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa1813751","volume":"380","author":"LV Moran","year":"2019","unstructured":"Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380:1128\u201338.","journal-title":"N Engl J Med"},{"key":"1214_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.30795","volume":"4","author":"M Tadrous","year":"2021","unstructured":"Tadrous M, Shakeri A, Chu C, Watt J, Mamdani MM, Juurlink DN, et al. Assessment of stimulant use and cardiovascular event risks among older adults. JAMA Netw Open. 2021;4: e2130795\u2013e95.","journal-title":"JAMA Netw Open"},{"key":"1214_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43597","volume":"5","author":"L Zhang","year":"2022","unstructured":"Zhang L, Yao H, Li L, Du Rietz E, Andell P, Garcia-Argibay M, et al. Risk of cardiovascular diseases associated with medications used in attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis. JAMA Netw Open. 2022;5: e2243597.","journal-title":"JAMA Netw Open"},{"key":"1214_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111018","volume":"253","author":"H Bakouni","year":"2023","unstructured":"Bakouni H, Sharafi H, Bahremand A, Drouin S, Ziegler D, Bach P, et al. Bupropion for treatment of amphetamine-type stimulant use disorder: a systematic review and meta-analysis of placebo-controlled randomized clinical trials. Drug Alcohol Depend. 2023;253: 111018.","journal-title":"Drug Alcohol Depend"},{"key":"1214_CR24","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1001\/archgenpsychiatry.2011.124","volume":"68","author":"GN Colfax","year":"2011","unstructured":"Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68:1168\u201375.","journal-title":"Arch Gen Psychiatry"},{"key":"1214_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/jamapsychiatry.2019.3655","volume":"77","author":"PO Coffin","year":"2020","unstructured":"Coffin PO, Santos G-M, Hern J, Vittinghoff E, Walker JE, Matheson T, et al. Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial. JAMA Psychiatr. 2020;77:246\u201355.","journal-title":"JAMA Psychiatr"},{"key":"1214_CR26","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1038\/npp.2015.83","volume":"40","author":"LA Ray","year":"2015","unstructured":"Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacology. 2015;40:2347\u201356.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1214_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/ADM.0000000000001422","volume":"19","author":"G Bastien","year":"2024","unstructured":"Bastien G, Mcanulty C, Sharafi H, Mahroug A, Elkrief L, Ziegler D, et al. Is naltrexone effective and safe for treating amphetamine-type stimulant use disorder? A systematic review and meta-analysis. J Addict Med. 2024;19(3):322\u201330.","journal-title":"J Addict Med"},{"key":"1214_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa2020214","volume":"384","author":"MH Trivedi","year":"2021","unstructured":"Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384:140\u201353.","journal-title":"N Engl J Med"},{"key":"1214_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101005","volume":"38","author":"R Mcketin","year":"2021","unstructured":"Mcketin R, Dean OM, Turner A, Kelly PJ, Quinn B, Lubman DI, et al. N-acetylcysteine (NAC) for methamphetamine dependence: a randomised controlled trial. EClinicalMedicine. 2021;38: 101005.","journal-title":"EClinicalMedicine"},{"key":"1214_CR30","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","volume":"11","author":"AM Trescot","year":"2008","unstructured":"Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11:S133\u201353.","journal-title":"Pain Physician"},{"key":"1214_CR31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/archpsyc.1972.01750220001001","volume":"26","author":"A Goldstein","year":"1972","unstructured":"Goldstein A. Heroin addiction and the role of methadone in its treatment. Arch Gen Psychiatry. 1972;26:291\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"1214_CR32","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2165\/00003495-200969100-00003","volume":"69","author":"C Jim\u00e9nez-Ruiz","year":"2009","unstructured":"Jim\u00e9nez-Ruiz C, Berlin I, Hering T. Varenicline: a novel pharmacotherapy for smoking cessation. Drugs. 2009;69:1319\u201338.","journal-title":"Drugs"},{"key":"1214_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/COPD.S1121","volume":"3","author":"S Wilkes","year":"2008","unstructured":"Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis. 2008;3:45\u201353.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"1214_CR34","first-page":"Cd006103","volume":"5","author":"K Cahill","year":"2010","unstructured":"Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2010;5(5):Cd006103.","journal-title":"Cochrane Database Syst Rev"},{"key":"1214_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110970","volume":"252","author":"JR Yates","year":"2023","unstructured":"Yates JR, Broderick MR, Berling KL, Gieske MG, Osborn E, Nelson MR, et al. Effects of adolescent methylphenidate administration on methamphetamine conditioned place preference in an animal model of attention-deficit\/hyperactivity disorder: examination of potential sex differences. Drug Alcohol Depend. 2023;252: 110970.","journal-title":"Drug Alcohol Depend"},{"key":"1214_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3720","volume":"4","author":"ES Calipari","year":"2013","unstructured":"Calipari ES, Ferris MJ, Salahpour A, Caron MG, Jones SR. Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun. 2013;4: 2720.","journal-title":"Nat Commun"},{"key":"1214_CR37","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1124\/jpet.102.045005","volume":"304","author":"V Sandoval","year":"2003","unstructured":"Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther. 2003;304:1181\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"1214_CR38","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMe1900502","volume":"380","author":"S Cortese","year":"2019","unstructured":"Cortese S. Psychosis during attention deficit-hyperactivity disorder treatment with stimulants. N Engl J Med. 2019;380:1178\u201380.","journal-title":"N Engl J Med"},{"key":"1214_CR39","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/j.1360-0443.2005.01160.x","volume":"100","author":"C Mcgregor","year":"2005","unstructured":"Mcgregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005;100:1320\u20139.","journal-title":"Addiction"},{"key":"1214_CR40","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/j.1360-0443.2010.03066.x","volume":"105","author":"T Zorick","year":"2010","unstructured":"Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G, et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction. 2010;105:1809\u201318.","journal-title":"Addiction"},{"key":"1214_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/02791072.2000.10400231","volume":"32","author":"ML Brecht","year":"2000","unstructured":"Brecht ML, Von Mayrhauser C, Anglin MD. Predictors of relapse after treatment for methamphetamine use. J Psychoactive Drugs. 2000;32:211\u201320.","journal-title":"J Psychoactive Drugs"},{"key":"1214_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0376-8716(00)00217-9","volume":"63","author":"DT Hartz","year":"2001","unstructured":"Hartz DT, Frederick-Osborne SL, Galloway GP. Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis. Drug Alcohol Depend. 2001;63:269\u201376.","journal-title":"Drug Alcohol Depend"},{"key":"1214_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/dar.13511","volume":"42","author":"LS Acheson","year":"2023","unstructured":"Acheson LS, Williams BH, Farrell M, Mcketin R, Ezard N, Siefried KJ. Pharmacological treatment for methamphetamine withdrawal: a systematic review and meta-analysis of randomised controlled trials. Drug Alcohol Rev. 2023;42:7\u201319.","journal-title":"Drug Alcohol Rev"},{"key":"1214_CR44","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1177\/02698811211050563","volume":"35","author":"RG Thompson Jr","year":"2021","unstructured":"Thompson RG Jr, Oliveto A, Thostenson JD, Wilson MP, Mcgaugh J, Mancino MJ. Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: a pilot clinical trial. J Psychopharmacol. 2021;35:1420\u201330.","journal-title":"J Psychopharmacol"},{"key":"1214_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109692","volume":"241","author":"LS Acheson","year":"2022","unstructured":"Acheson LS, Ezard N, Lintzeris N, Dunlop A, Brett J, Rodgers C, et al. Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: a pilot feasibility and safety trial. Drug Alcohol Depend. 2022;241: 109692.","journal-title":"Drug Alcohol Depend"},{"key":"1214_CR46","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.neuropharm.2013.05.024","volume":"76 Pt B","author":"GF Koob","year":"2014","unstructured":"Koob GF, Buck CL, Cohen A, Edwards S, Park PE, Schlosburg JE, et al. Addiction as a stress surfeit disorder. Neuropharmacology. 2014;76 Pt B:370\u201382.","journal-title":"Neuropharmacology"},{"key":"1214_CR47","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760\u201373.","journal-title":"Lancet Psychiatry"},{"key":"1214_CR48","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00210-018-1470-z","volume":"391","author":"JA Garc\u00eda-Carmona","year":"2018","unstructured":"Garc\u00eda-Carmona JA, Georgiou P, Zanos P, Bailey A, Laorden ML. Methamphetamine withdrawal induces activation of CRF neurons in the brain stress system in parallel with an increased activity of cardiac sympathetic pathways. Naunyn Schmiedebergs Arch Pharmacol. 2018;391:423\u201334.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1214_CR49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.pbb.2012.01.003","volume":"101","author":"Y Nawata","year":"2012","unstructured":"Nawata Y, Kitaichi K, Yamamoto T. Increases of CRF in the amygdala are responsible for reinstatement of methamphetamine-seeking behavior induced by footshock. Pharmacol Biochem Behav. 2012;101:297\u2013302.","journal-title":"Pharmacol Biochem Behav"},{"key":"1214_CR50","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.neuropharm.2016.02.012","volume":"105","author":"P Georgiou","year":"2016","unstructured":"Georgiou P, Zanos P, Garcia-Carmona JA, Hourani S, Kitchen I, Laorden ML, et al. Methamphetamine abstinence induces changes in \u03bc-opioid receptor, oxytocin and CRF systems: association with an anxiogenic phenotype. Neuropharmacology. 2016;105:520\u201332.","journal-title":"Neuropharmacology"},{"key":"1214_CR51","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.1523\/JNEUROSCI.21-23-09414.2001","volume":"21","author":"ND Volkow","year":"2001","unstructured":"Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001;21:9414\u20138.","journal-title":"J Neurosci"},{"key":"1214_CR52","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1176\/appi.ajp.160.9.1699","volume":"160","author":"Y Sekine","year":"2003","unstructured":"Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry. 2003;160:1699\u2013701.","journal-title":"Am J Psychiatry"},{"key":"1214_CR53","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1523\/JNEUROSCI.21-16-05916.2001","volume":"21","author":"Y Schmitz","year":"2001","unstructured":"Schmitz Y, Lee CJ, Schmauss C, Gonon F, Sulzer D. Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci. 2001;21:5916\u201324.","journal-title":"J Neurosci"},{"key":"1214_CR54","doi-asserted-by":"publisher","first-page":"12070","DOI":"10.1074\/jbc.M212815200","volume":"278","author":"H Khoshbouei","year":"2003","unstructured":"Khoshbouei H, Wang H, Lechleiter JD, Javitch JA, Galli A. Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem. 2003;278:12070\u20137.","journal-title":"J Biol Chem"},{"key":"1214_CR55","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pnpbp.2017.11.010","volume":"87","author":"SJ Luikinga","year":"2018","unstructured":"Luikinga SJ, Kim JH, Perry CJ. Developmental perspectives on methamphetamine abuse: exploring adolescent vulnerabilities on brain and behavior. Prog Neuropsychopharmacol Biol Psychiatry. 2018;87:78\u201384.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1214_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109436","volume":"227","author":"S Dominguez-Lopez","year":"2023","unstructured":"Dominguez-Lopez S, Ahn B, Sataranatarajan K, Ranjit R, Premkumar P, Van Remmen H, et al. Long-term methamphetamine self-administration increases mesolimbic mitochondrial oxygen consumption and decreases striatal glutathione. Neuropharmacology. 2023;227: 109436.","journal-title":"Neuropharmacology"},{"key":"1214_CR57","doi-asserted-by":"publisher","DOI":"10.21767\/2471-853X.100016","author":"R Malcolm","year":"2016","unstructured":"Malcolm R, Myrick H, Li X, Henderson S, Brady KT, George MS, et al. Regional brain activity in abstinent methamphetamine dependent males following cue exposure. J Drug Abuse. 2016. https:\/\/doi.org\/10.21767\/2471-853X.100016.","journal-title":"J Drug Abuse"},{"key":"1214_CR58","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12888-020-02743-5","volume":"20","author":"T Chen","year":"2020","unstructured":"Chen T, Su H, Zhong N, Tan H, Li X, Meng Y, et al. Disrupted brain network dynamics and cognitive functions in methamphetamine use disorder: insights from EEG microstates. BMC Psychiatry. 2020;20:334.","journal-title":"BMC Psychiatry"},{"key":"1214_CR59","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1001\/jamapsychiatry.2017.0135","volume":"74","author":"AH Ashok","year":"2017","unstructured":"Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatr. 2017;74:511\u20139.","journal-title":"JAMA Psychiatr"},{"key":"1214_CR60","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1176\/appi.ajp.158.3.377","volume":"158","author":"ND Volkow","year":"2001","unstructured":"Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158:377\u201382.","journal-title":"Am J Psychiatry"},{"key":"1214_CR61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/archpsyc.63.1.90","volume":"63","author":"Y Sekine","year":"2006","unstructured":"Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, Futatsubashi M, et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2006;63:90\u2013100.","journal-title":"Arch Gen Psychiatry"},{"key":"1214_CR62","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","volume":"99","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Michaelides M, Baler R. The neuroscience of drug reward and addiction. Physiol Rev. 2019;99:2115\u201340.","journal-title":"Physiol Rev"},{"key":"1214_CR63","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1515\/RNS.2011.055","volume":"22","author":"MA Parvaz","year":"2011","unstructured":"Parvaz MA, Alia-Klein N, Woicik PA, Volkow ND, Goldstein RZ. Neuroimaging for drug addiction and related behaviors. Rev Neurosci. 2011;22:609\u201324.","journal-title":"Rev Neurosci"},{"key":"1214_CR64","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.biopsych.2005.04.039","volume":"58","author":"ED London","year":"2005","unstructured":"London ED, Berman SM, Voytek B, Simon SL, Mandelkern MA, Monterosso J, et al. Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry. 2005;58:770\u20138.","journal-title":"Biol Psychiatry"},{"key":"1214_CR65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1001\/archpsyc.61.1.73","volume":"61","author":"ED London","year":"2004","unstructured":"London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004;61:73\u201384.","journal-title":"Arch Gen Psychiatry"},{"key":"1214_CR66","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/sj.mp.4002107","volume":"13","author":"SM Berman","year":"2008","unstructured":"Berman SM, Voytek B, Mandelkern MA, Hassid BD, Isaacson A, Monterosso J, et al. Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse. Mol Psychiatry. 2008;13:897\u2013908.","journal-title":"Mol Psychiatry"},{"key":"1214_CR67","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drugalcdep.2014.02.702","volume":"139","author":"ML Brecht","year":"2014","unstructured":"Brecht ML, Herbeck D. Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug Alcohol Depend. 2014;139:18\u201325.","journal-title":"Drug Alcohol Depend"},{"key":"1214_CR68","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1111\/j.1360-0443.2012.03933.x","volume":"107","author":"R Mcketin","year":"2012","unstructured":"Mcketin R, Najman JM, Baker AL, Lubman DI, Dawe S, Ali R, et al. Evaluating the impact of community-based treatment options on methamphetamine use: findings from the methamphetamine treatment evaluation study (MATES). Addiction. 2012;107:1998\u20132008.","journal-title":"Addiction"},{"key":"1214_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068791","volume":"8","author":"G Wang","year":"2013","unstructured":"Wang G, Shi J, Chen N, Xu L, Li J, Li P, et al. Effects of length of abstinence on decision-making and craving in methamphetamine abusers. PLoS ONE. 2013;8: e68791.","journal-title":"PLoS ONE"},{"key":"1214_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2024.100022","volume":"77","author":"JJ Chow","year":"2025","unstructured":"Chow JJ, Pitts KM, Negishi K, Madangopal R, Dong Y, Wolf ME, et al. Neurobiology of the incubation of drug craving: an update. Pharmacol Rev. 2025;77: 100022.","journal-title":"Pharmacol Rev"},{"key":"1214_CR71","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jamapsychiatry.2022.1240","volume":"79","author":"N Vafaie","year":"2022","unstructured":"Vafaie N, Kober H. Association of drug cues and craving with drug use and relapse: a systematic review and meta-analysis. JAMA Psychiatr. 2022;79:641\u201350.","journal-title":"JAMA Psychiatr"},{"issue":"Suppl 1","key":"1214_CR72","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neuropharm.2008.07.011","volume":"56","author":"PW Kalivas","year":"2009","unstructured":"Kalivas PW, Lalumiere RT, Knackstedt L, Shen H. Glutamate transmission in addiction. Neuropharmacology. 2009;56(Suppl 1):169\u201373.","journal-title":"Neuropharmacology"},{"key":"1214_CR73","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamapsychiatry.2013.2207","volume":"70","author":"RM Brown","year":"2013","unstructured":"Brown RM, Kupchik YM, Kalivas PW. The story of glutamate in drug addiction and of n-acetylcysteine as a potential pharmacotherapyglutamate and N-acetylcysteine in drug addiction. JAMA Psychiat. 2013;70:895\u20137.","journal-title":"JAMA Psychiat"},{"key":"1214_CR74","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41380-024-02708-0","volume":"30","author":"J Ye","year":"2025","unstructured":"Ye J, Garrison KA, Lacadie C, Potenza MN, Sinha R, Goldfarb EV, et al. Network state dynamics underpin basal craving in a transdiagnostic population. Mol Psychiatry. 2025;30:619\u201328.","journal-title":"Mol Psychiatry"},{"key":"1214_CR75","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41593-022-01228-w","volume":"26","author":"L Koban","year":"2023","unstructured":"Koban L, Wager TD, Kober H. A neuromarker for drug and food craving distinguishes drug users from non-users. Nat Neurosci. 2023;26:316\u201325.","journal-title":"Nat Neurosci"},{"key":"1214_CR76","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41593-022-01246-8","volume":"26","author":"G Kronberg","year":"2023","unstructured":"Kronberg G, Goldstein RZ. An fMRI marker of drug and food craving. Nat Neurosci. 2023;26:178\u201380.","journal-title":"Nat Neurosci"},{"key":"1214_CR77","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/add.16626","volume":"120","author":"ND Volkow","year":"2025","unstructured":"Volkow ND, Xu R. GLP-1R agonist medications for addiction treatment. Addiction. 2025;120:198\u2013200.","journal-title":"Addiction"},{"key":"1214_CR78","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.4789","author":"CS Hendershot","year":"2025","unstructured":"Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatr. 2025. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.4789.","journal-title":"JAMA Psychiatr"},{"key":"1214_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2024.102898","volume":"87","author":"EJ Young","year":"2024","unstructured":"Young EJ, Radnai L, Prikhodko V, Miller CA. Novel therapeutics in development for the treatment of stimulant-use disorder. Curr Opin Neurobiol. 2024;87: 102898.","journal-title":"Curr Opin Neurobiol"},{"key":"1214_CR80","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.addicn.2023.100126","volume":"8","author":"LG Knowles","year":"2023","unstructured":"Knowles LG, Armanious AJ, Peng Y, Welsh WJ, James MH. Recent advances in drug discovery efforts targeting the sigma 1 receptor system: implications for novel medications designed to reduce excessive drug and food seeking. Addict Neurosci. 2023;8:100126.","journal-title":"Addict Neurosci"},{"key":"1214_CR81","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2174\/1871527314666150529144655","volume":"14","author":"DJ Roberts-Wolfe","year":"2015","unstructured":"Roberts-Wolfe DJ, Kalivas PW. Glutamate transporter GLT-1 as a therapeutic target for substance use disorders. CNS Neurol Disord Drug Targets. 2015;14:745\u201356.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1214_CR82","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/ajad.12620","volume":"26","author":"MS Duailibi","year":"2017","unstructured":"Duailibi MS, Cordeiro Q, Brietzke E, Ribeiro M, Larowe S, Berk M, et al. N-acetylcysteine in the treatment of craving in substance use disorders: systematic review and meta-analysis. Am J Addict. 2017;26:660\u20136.","journal-title":"Am J Addict"},{"key":"1214_CR83","first-page":"28","volume":"18","author":"SG Mousavi","year":"2015","unstructured":"Mousavi SG, Sharbafchi MR, Salehi M, Peykanpour M, Karimian Sichani N, Maracy M. The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study. Arch Iran Med. 2015;18:28\u201333.","journal-title":"Arch Iran Med"},{"key":"1214_CR84","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/mp.2015.103","volume":"21","author":"EJ Young","year":"2016","unstructured":"Young EJ, Blouin AM, Briggs SB, Daws SE, Lin L, Cameron MD, et al. Nonmuscle myosin IIB as a therapeutic target for the prevention of relapse to methamphetamine use. Mol Psychiatry. 2016;21:615\u201323.","journal-title":"Mol Psychiatry"},{"key":"1214_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.conb.2017.10.006","volume":"49","author":"AJ Langdon","year":"2018","unstructured":"Langdon AJ, Sharpe MJ, Schoenbaum G, Niv Y. Model-based predictions for dopamine. Curr Opin Neurobiol. 2018;49:1\u20137.","journal-title":"Curr Opin Neurobiol"},{"key":"1214_CR86","doi-asserted-by":"publisher","first-page":"4982453","DOI":"10.1155\/2018\/4982453","volume":"2018","author":"F Limanaqi","year":"2018","unstructured":"Limanaqi F, Gambardella S, Biagioni F, Busceti CL, Fornai F. Epigenetic effects induced by methamphetamine and methamphetamine-dependent oxidative stress. Oxid Med Cell Longev. 2018;2018:4982453.","journal-title":"Oxid Med Cell Longev"},{"key":"1214_CR87","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3109\/00952990.2015.1044607","volume":"41","author":"MG Hall","year":"2015","unstructured":"Hall MG, Alhassoon OM, Stern MJ, Wollman SC, Kimmel CL, Perez-Figueroa A, et al. Gray matter abnormalities in cocaine versus methamphetamine-dependent patients: a neuroimaging meta-analysis. Am J Drug Alcohol Abuse. 2015;41:290\u20139.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1214_CR88","first-page":"2067","volume":"18","author":"GR Mahmoudiasl","year":"2019","unstructured":"Mahmoudiasl GR, Abbaszadeh HA, Rezaei-Tavirani M, Abdollahifar MA, Sadeghi Y, Khoramgah MS, et al. Postmortem study of molecular and histological changes in the CA1 hippocampal region of chronic methamphetamine user. Iran J Pharm Res. 2019;18:2067\u201382.","journal-title":"Iran J Pharm Res"},{"key":"1214_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2020.101802","volume":"107","author":"S Khoshsirat","year":"2020","unstructured":"Khoshsirat S, Khoramgah MS, Mahmoudiasl GR, Rezaei-Tavirani M, Abdollahifar MA, Tahmasebinia F, et al. LC3 and ATG5 overexpression and neuronal cell death in the prefrontal cortex of postmortem chronic methamphetamine users. J Chem Neuroanat. 2020;107: 101802.","journal-title":"J Chem Neuroanat"},{"key":"1214_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2021.101942","volume":"114","author":"FS Tabatabaei Mirakabad","year":"2021","unstructured":"Tabatabaei Mirakabad FS, Khoramgah MS, Abdollahifar MA, Tehrani AS, Rezaei-Tavirani M, Niknazar S, et al. NUPR1- CHOP experssion, autophagosome formation and apoptosis in the postmortem striatum of chronic methamphetamine user. J Chem Neuroanat. 2021;114: 101942.","journal-title":"J Chem Neuroanat"},{"key":"1214_CR91","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/02791072.2015.1071447","volume":"47","author":"YC Chen","year":"2015","unstructured":"Chen YC, Chen CK, Wang LJ. Predictors of relapse and dropout during a 12-week relapse prevention program for methamphetamine users. J Psychoactive Drugs. 2015;47:317\u201324.","journal-title":"J Psychoactive Drugs"},{"key":"1214_CR92","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pnpbp.2016.04.005","volume":"69","author":"N Zhong","year":"2016","unstructured":"Zhong N, Jiang H, Du J, Zhao Y, Sun H, Xu D, et al. The cognitive impairments and psychological wellbeing of methamphetamine dependent patients compared with health controls. Prog Neuropsychopharmacol Biol Psychiatry. 2016;69:31\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1214_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2021.107075","volume":"123","author":"AA Guerin","year":"2021","unstructured":"Guerin AA, Drummond KD, Bonomo Y, Lawrence AJ, Rossell SL, Kim JH. Assessing methamphetamine-related cue reactivity in people with methamphetamine use disorder relative to controls. Addict Behav. 2021;123: 107075.","journal-title":"Addict Behav"},{"key":"1214_CR94","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3389\/fpsyt.2019.00880","volume":"10","author":"AA Guerin","year":"2019","unstructured":"Guerin AA, Bonomo Y, Lawrence AJ, Baune BT, Nestler EJ, Rossell SL, et al. Cognition and related neural findings on methamphetamine use disorder: insights and treatment implications from schizophrenia research. Front Psychiatry. 2019;10:880.","journal-title":"Front Psychiatry"},{"key":"1214_CR95","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1521-0391.2010.00052.x","volume":"19","author":"AD Kalechstein","year":"2010","unstructured":"Kalechstein AD, De La Garza II R, Newton TF. Modafinil administration improves working memory in methamphetamine-dependent individuals who demonstrate baseline impairment. Am J Addict. 2010;19:340\u20134.","journal-title":"Am J Addict"},{"key":"1214_CR96","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/npp.2010.233","volume":"36","author":"DG Ghahremani","year":"2011","unstructured":"Ghahremani DG, Tabibnia G, Monterosso J, Hellemann G, Poldrack RA, London ED. Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals. Neuropsychopharmacology. 2011;36:950\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"1214_CR97","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/07067437241262967","volume":"69","author":"L Elkrief","year":"2024","unstructured":"Elkrief L, Sharafi H, Bakouni H, Mcanulty C, Bastien G, Dubreucq S, et al. Efficacy and safety of modafinil for treatment of amphetamine-type stimulant use disorder: a systematic review and meta-analysis of randomized placebo-controlled trials: Efficacit\u00e9 et innocuit\u00e9 du modafinil pour le traitement des troubles li\u00e9s \u00e0 l\u2019usage de stimulants de type amph\u00e9tamine\u202f: revue syst\u00e9matique et m\u00e9ta-analyse d\u2019essais randomis\u00e9s contr\u00f4l\u00e9s par placebo. Can J Psychiatry. 2024;69:793\u2013805.","journal-title":"Can J Psychiatry"},{"key":"1214_CR98","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.maturitas.2018.12.003","volume":"121","author":"M Papageorgiou","year":"2019","unstructured":"Papageorgiou M, Raza A, Fraser S, Nurgali K, Apostolopoulos V. Methamphetamine and its immune-modulating effects. Maturitas. 2019;121:13\u201321.","journal-title":"Maturitas"},{"key":"1214_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911224","author":"M Davidson","year":"2022","unstructured":"Davidson M, Mayer M, Habib A, Rashidi N, Filippone RT, Fraser S, et al. Methamphetamine induces systemic inflammation and anxiety: the role of the gut\u2013immune\u2013brain axis. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231911224.","journal-title":"Int J Mol Sci"},{"key":"1214_CR100","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/187231280702140520191324","volume":"7","author":"H Solhi","year":"2014","unstructured":"Solhi H, Malekirad A, Kazemifar AM, Sharifi F. Oxidative stress and lipid peroxidation in prolonged users of methamphetamine. Drug Metab Lett. 2014;7:79\u201382.","journal-title":"Drug Metab Lett"},{"key":"1214_CR101","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/pcn.12025","volume":"67","author":"MC Huang","year":"2013","unstructured":"Huang MC, Lin SK, Chen CH, Pan CH, Lee CH, Liu HC. Oxidative stress status in recently abstinent methamphetamine abusers. Psychiatry Clin Neurosci. 2013;67:92\u2013100.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1214_CR102","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1096\/fj.03-0295com","volume":"18","author":"S Jayanthi","year":"2004","unstructured":"Jayanthi S, Deng X, Noailles PA, Ladenheim B, Cadet JL. Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J. 2004;18:238\u201351.","journal-title":"FASEB J"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01214-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01214-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01214-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:04:36Z","timestamp":1760177076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01214-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,14]]},"references-count":102,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01214-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,14]]},"assertion":[{"value":"31 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.B. has received grants from Meat and Livestock Board, Woolworths, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma and Servier; received speaker support from Lundbeck, Controversias Barcelona, Servier, Medisquire, Janssen, Medplan, Abbott India, Sandoz, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Pfizer, Sanofi-Synthelabo Solvay and Wyeth and consulted to Milken Institute, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Bioadvantex, Merck, Glaxo SmithKline, Lundbeck, Janssen, Cilag, and Servier. M.B.\u00a0is an Editorial Board member of\n                      CNS Drugs\n                      . M.B. was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Other authors have no interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. M.B. is supported by a NHMRC Leadership 3 Investigator grant (GNT2017131) and J.H.K. is supported by an ARC Future Fellowship (FT220100351). No funding was received for the preparation of this article. Open access publication was supported by a Read and Publish agreement held by UNSW.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"R.M.: conceptualisation and writing\u2014original draft, review and editing. M.B.: writing\u2014original draft text on neuro-inflammation and neurotoxicity, review and editing, and supervision. J.H.K.: visualisation and writing\u2014review and editing. A.T.: writing\u2014review and editing. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}